Log in Free sign up

IMV (IMV) News and press releases

News

From Benzinga Pro

IMV: Q1 Earnings Insights

IMV (NASDAQ:IMV) reported its Q1 earnings results on Friday, May 13, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IMV reported in-line EPS of $-0.13 versus an estimate of $-0.13.

Recap: IMV Q1 Earnings

IMV (NASDAQ:IMV) reported its Q1 earnings results on Friday, May 13, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings IMV reported in-line EPS of $-0.13 versus an estimate of $-0.13.

IMV Q1 EPS $(0.13) Down From $(0.10) YoY, Sales $24.00K Down From $69.00K YoY

IMV (NASDAQ:IMV) reported quarterly losses of $(0.13) per share. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $24.00 thousand in sales this quarter.

Earnings Scheduled For May 13, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million.

IMV Earnings Preview

IMV (NASDAQ:IMV) is set to give its latest quarterly earnings report on Friday, 2022-05-13. Here's what investors need to know before the announcement. Analysts estimate that IMV will report an earnings per share (EPS) of $-0.13.

IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti Tumor Activity

Biotech, News, Penny Stocks, Health Care, General

IMV Inc (NASDAQ: IMV) announced

IMV Inc. To Present On Clinical Benefit Of MVP-S in Combination With Pembrolizumab in Bladder Cancer at AACR Annual Meeting Apr. 12

Biotech, News, Events, General

Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The

Recap: IMV Q4 Earnings

IMV (NASDAQ:IMV) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Earnings Scheduled For March 17, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ:TGA) is estimated to report earnings for its fourth quarter.

Earnings Preview For IMV

IMV (NASDAQ:IMV) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement. Analysts estimate that IMV will report an earnings per share (EPS) of $-0.13.

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

IMV To Showcase Its DPX Delivery Technology In Two Presentations At The AACR Annual Meeting 2022

IMV's DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company's basket study in advanced,

Press releases

From Benzinga Pro

IMV Inc. to Present at the H.C. Wainwright Global Investment Conference

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that members of

IMV Inc. Announces First Quarter 2022 Financial and Operational Results

Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in

IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today

IMV's Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company's

IMV Inc. Names Michael P. Bailey Chairman of The Board

IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today

IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting

Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpoint inhibitor therapy The

IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the Company

IMV Inc. to Present at Two Upcoming Investor Conferences

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that members of IMV's

IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results

First patient dosed in VITALIZE Phase 2B trial in relapsed/refractory DLBCL Metastatic bladder cancer cohort data from Phase 2 basket trial to be presented at late-breaking symposium at AACR Phase 2B Avalon trial

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

IMV's DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company's basket study in advanced, metastatic